Related Experiment Videos
Iron chelation therapy
1Department of Haematology, Royal Free Hospital and School of Medicine, London, UK.
Journal of Internal Medicine. Supplement
|January 1, 1997
Summary
Desferrioxamine (DFX) and deferiprone are iron chelators for transfusional iron overload. Combined therapy shows promise for reducing iron burden, with deferiprone side effects mainly in heavily iron-loaded patients.
Area of Science:
- Hematology
- Pharmacology
- Clinical Medicine
Background:
- Transfusional iron overload is a common complication in patients requiring frequent blood transfusions, particularly those with thalassemia major.
- Effective iron chelation therapy is crucial to prevent organ damage and improve patient outcomes.
- Desferrioxamine (DFX) is an established intravenous iron chelator, while deferiprone offers oral administration but with varying efficacy.
Purpose of the Study:
- To evaluate the efficacy and safety of deferiprone, a less effective but orally active iron chelator.
- To explore the potential of combined therapy with deferiprone and DFX for enhanced iron reduction.
- To assess the side-effect profile of deferiprone, particularly in relation to pre-existing iron load.
Main Methods:
- Review of long-term trials assessing deferiprone efficacy at doses up to 100 mg/kg/day.
- Investigation of combined therapy regimens involving daily deferiprone and intermittent DFX.
- Monitoring of body iron stores via liver biopsy, serum ferritin, and urine iron excretion.
- Analysis of deferiprone side effects, including arthropathy, gastrointestinal symptoms, and neutropenia.
Main Results:
- Deferiprone can maintain safe body iron stores in a proportion of thalassemia major patients, but high iron levels persist in others.
- Combined therapy with deferiprone and DFX demonstrates additive urine iron excretion, suggesting chelation of different iron pools.
- Patients with lower baseline serum ferritin (<2500 µg/L) experience fewer deferiprone side effects.
- Arthropathy and hematological issues are the primary reasons for deferiprone discontinuation, predominantly in heavily iron-loaded patients.
Conclusions:
- Continuous intravenous DFX is essential for patients with cardiac complications due to iron overload.
- Combined deferiprone and DFX therapy is safe and potentially more effective in reducing body iron burden.
- Careful patient selection and monitoring are necessary to manage deferiprone's side effects, especially in highly iron-loaded individuals.
- Ongoing research focuses on developing new oral chelators and improved DFX delivery methods.